Karien Bloem

Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells

Juan J. García‐Vallejo, Martino Ambrosini, Annemieke Overbeek et al. · Molecular Immunology · 2012 · 109 citations

Cell-based Drug Delivery, Nanomedicine, Multivalent Glycopeptide Dendrimers +9

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study

Nina Wilkinson, Teresa Tsakok, Nick Dand et al. · Journal of Investigative Dermatology · 2018 · 82 citations · Full text

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

Karien Bloem, Astrid van Leeuwen, Gerrit Verbeek et al. · Journal of Immunological Methods · 2015 · 74 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

Lea C. Berkhout, M. l’Ami, J. Ruwaard et al. · Science Translational Medicine · 2019 · 60 citations · Full text

DCIR interacts with ligands from both endogenous and pathogenic origin

Karien Bloem, Ilona M. Vuist, Meike van den Berk et al. · Immunology Letters · 2013 · 56 citations

Host Response, Microbial Pathogens, Pathogenesis +8